Results 61 to 70 of about 121,777 (350)

Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age. [PDF]

, 2015
BACKGROUND:Hizentra® (IGSC 20%) is a 20% liquid IgG product approved for subcutaneous administration in adults and children 2 years of age and older who have primary immunodeficiency disease (PIDD). There is limited information about the use of IGSC 20 %
Atkinson, Thomas Prescott, Bonilla, Francisco A, Dorsey, Morna, Gallagher, Joel L, Haddad, Elie, Heimall, Jennifer, Kobrynski, Lisa, Morris, David, Ochs, Hans D, Patel, Niraj C, Wahlstrom, Justin   +10 more
core   +2 more sources

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Kawasaki disease: do the manifestations in children observed in the Russian Federation and in foreign countries coincide?

Лечащий Врач
Background. Mucocutaneous lymphonodular syndrome (Kawasaki syndrome/disease) occurs most commonly in children under 5 years of age. Approximately one-third of patients who fail therapy form coronary artery aneurysms.
N. Yu. Golovanova, A. G. Samedova, Yu. O. Kostina   +2 more
doaj   +1 more source

Maintenance therapy with subcutaneous immunoglobulin in a patient with immune‐mediated neuropathic postural tachycardia syndrome

Journal of Translational Autoimmunity, 2021
Aims: We describe the disease course of a 35-year-old female with an autoimmune mediated neuropathic postural tachycardia syndrome (PoTS), who responded to immunoglobulin therapy and stabilized on maintenance therapy with subcutaneous immunoglobulin ...
Kalliopi Pitarokoili, Andrea Maier, Elena C. de Moya Rubio, Katrin Hahn, Gerd Wallukat, Diamantis Athanasopoulos, Thomas Grüter, Jeremias Motte, Anna Lena Fisse, Ralf Gold   +9 more
doaj   +1 more source

A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations [PDF]

, 2019
Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission. Exacerbations may involve increasing bulbar weakness and/or sudden respiratory failure, both of which can be critically disabling.
Ayguasanosa, J, Balasa, R, Bril, V, Camprubi, S, Chen, J, De Bleecker, Jan, Garcia, B, Griffin, R, Heckmann, JM, Henriquez, W, Karelis, G, Lagrange, E, Mondou, E, Nicolle, M, Stuchevskaya, T, Van Damme, P, Vilciu, C, Villa, A   +17 more
core   +2 more sources

Life‐Threatening Bradycardia in Anti‐NMDA‐Receptor Encephalitis and a Novel Use for Permanent Pacing

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Pediatric anti‐NMDA receptor encephalitis (pNMDARE) is an autoantibody‐mediated disorder that can cause severe autonomic dysfunction, including symptomatic bradycardia and asystole. Dysautonomia can last for years, making it very challenging to manage.
Sarah Tucker, Abhijit Das, Andres Jimenez, Areeba Basit, Yike Jiang, Emily A. Smitherman, Heather Van Mater, Taylor Howard, Alexander J. Sandweiss, Kristen S. Fisher   +9 more
wiley   +1 more source

Intravenous Immunoglobulin Therapy for Diabetic Amyotrophy.

Internal Medicine, 2001
A 49-year-old woman with diabetes mellitus developed progressive weakness and atrophy of both thighs rendering her wheelchair-bound within two months. The neurological findings and electrophysiological test results were compatible with diabetic amyotrophy (DA). Immediately after intravenous immunoglobulin (IVIg) therapy (20 g x 3 days), she became able
T, Ogawa, T, Taguchi, Y, Tanaka, K, Ikeguchi, I, Nakano   +4 more
openaire   +3 more sources

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Idiotype-specific intravenous immunoglobulin for therapy of immunoglobulin kappa free light chain deficiency

Human Vaccines & Immunotherapeutics, 2019
Deficient antibody production in patients with common variable immunodeficiency (CVID) is accompanied by an inability to produce free light chains (FLCs), particularly kappa (κ) FLC, due to B-cell dysfunction.
Adina Elena Stanciu, Monica Popescu, Dan Cristian Gheorghe   +2 more
doaj   +1 more source

Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. [PDF]

, 2019
Background Accurate prediction of coronary artery aneurysms ( CAAs ) in patients with Kawasaki disease remains challenging in North American cohorts. We sought to develop and validate a risk model for CAA prediction.
Baker, Annette L, Burns, Jane C, de Ferranti, Sarah, Dedeoglu, Fatma, Friedman, Kevin G, Gauvreau, Kimberlee, Lo, Mindy, Newburger, Jane W, Son, Mary Beth F, Sundel, Robert P, Tremoulet, Adriana H   +10 more
core